[SCHEDULE 13G/A Amendment No. 10 China Cord Blood Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 698659109 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a]
[Confidential Agreement to Purchase Assets by Share Issuance and Cash Payment In relation to Nanjing Xinjiekou Department Store Co., Ltd. By and among Nanjing Xinjiekou Department Store Co., Ltd. Golden Meditech Stem Cells (BVI) Company Limited and Golden Meditech Holdings Limited January 2016 Confidential Table of Contents ARTICLE 1 DEFINITIONS 2 ARTICLE 2 TRANSACTION ARRANGEMENTS 7 ARTICLE 3 CLOSING CONDITIONS] [Confidential Share Sale and Purchase Agreement In relation to China Cord Blood Corporation By and among Nanjing Xinjiekou Department Store Co., Ltd. and Golden Meditech Stem Cells (BVI) Company Limited Golden Meditech Holdings Limited January 2016 Confidential Table of Contents ARTICLE 1 DEFINITIONS 2 ARTICLE 2 TRANSACTION ARRANGEMENTS 6 ARTICLE 3 CLOSING CONDITIONS 9] [Profit Compensation Agreement By and between Nanjing Xinjiekou Department Store Co., Ltd. and Golden Meditech Stem Cells (BVI) Company Limited January 2016 Profit Compensation Agreement Profit Compensation Agreement Agreement This Party A: Nanjing Xinjiekou Department Store Co., Ltd. Address: 1 South Zhongshan Road, Qinhuai District, Nanjing, Jiangsu Province Legal Representative: Huaizhen Yang Party B: Golden Meditech Stem Cells (BVI) Company] [Dated this [ ] B E T W E E N : [ ] (as Chargor) AND GOLDEN MEDITECH STEM CELLS (BVI) LIMITED (as Chargee) AND CHINA CORD BLOOD CORPORATION SHARE CHARGE over TABLE OF CONTENTS 1. INTERPRETATION 1 2. 4 3. CHARGORS COVENANTS 5 4. COMPANYS COVENANTS 6] [Dated this [ ] B E T W E E N : [ ] (as Chargor) AND GOLDEN MEDITECH STEM CELLS (BVI) LIMITED (as Chargee) AND CHINA CORD BLOOD CORPORATION SHARE CHARGE over shares representing [34.6%] of the issued share capital of China Cord Blood Corporation TABLE OF CONTENTS 1. INTERPRETATION 1 2. 4 3. CHARGORS COVENANTS 5 4. COMPANYS] []
[Confidential Agreement to Purchase Assets by Share Issuance and Cash Payment In relation to Nanjing Xinjiekou Department Store Co., Ltd. By and among Nanjing Xinjiekou Department Store Co., Ltd. Golden Meditech Stem Cells (BVI) Company Limited and Golden Meditech Holdings Limited January 2016 Confidential Table of Contents ARTICLE 1 DEFINITIONS 2 ARTICLE 2 TRANSACTION ARRANGEMENTS 7 ARTICLE 3 CLOSING CONDITIONS] [Confidential Share Sale and Purchase Agreement In relation to China Cord Blood Corporation By and among Nanjing Xinjiekou Department Store Co., Ltd. and Golden Meditech Stem Cells (BVI) Company Limited Golden Meditech Holdings Limited January 2016 Confidential Table of Contents ARTICLE 1 DEFINITIONS 2 ARTICLE 2 TRANSACTION ARRANGEMENTS 6 ARTICLE 3 CLOSING CONDITIONS 9] [Profit Compensation Agreement By and between Nanjing Xinjiekou Department Store Co., Ltd. and Golden Meditech Stem Cells (BVI) Company Limited January 2016 Profit Compensation Agreement Profit Compensation Agreement Agreement This Party A: Nanjing Xinjiekou Department Store Co., Ltd. Address: 1 South Zhongshan Road, Qinhuai District, Nanjing, Jiangsu Province Legal Representative: Huaizhen Yang Party B: Golden Meditech Stem Cells (BVI) Company] [Dated this [ ] B E T W E E N : [ ] (as Chargor) AND GOLDEN MEDITECH STEM CELLS (BVI) LIMITED (as Chargee) AND CHINA CORD BLOOD CORPORATION SHARE CHARGE over TABLE OF CONTENTS 1. INTERPRETATION 1 2. 4 3. CHARGORS COVENANTS 5 4. COMPANYS COVENANTS 6] [Dated this [ ] B E T W E E N : [ ] (as Chargor) AND GOLDEN MEDITECH STEM CELLS (BVI) LIMITED (as Chargee) AND CHINA CORD BLOOD CORPORATION SHARE CHARGE over shares representing [34.6%] of the issued share capital of China Cord Blood Corporation TABLE OF CONTENTS 1. INTERPRETATION 1 2. 4 3. CHARGORS COVENANTS 5 4. COMPANYS] []
[FORM 6-K/A (Amendment No. 1) For the month of December 2015 CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower Form 20-F x Form 40-F o o o Yes ¨ No ý EXPLANATORY NOTE]
[FORM 6-K/A (Amendment No. 1) For the month of December 2015 CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower Form 20-F x Form 40-F o o o Yes ¨ No ý EXPLANATORY NOTE]
[China Cord Blood Corporation Announces Results of 201 5 Annual General Meeting HONG KONG, China, December 10 , 201 5 - China Cord Blood Corporation At the Annual General Meeting, shareholders · · About China Cord Blood Corporation China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and] [FORM 6-K 5 CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x o o o Yes o x Other Events On December 1 Description]
[Execution Version NOTE SUBSCRIPTION AGREEMENT among COM COMPANY LIMITED and GOLDEN MEDITECH HOLDINGS LIMITED and MR. KAM YUEN and BLUE OCEAN STRUCTURE INVESTMENT COMPANY LTD Dated December 4, 2015 TABLE OF CONTENTS 1. Interpretations 2 2. The Notes 8 3.] []
[9 Execution Share Sale Agreement Relating to China Cord Blood Corporation Purchaser Golden Meditech Holdings Limited ( Vendor Kam Yuen ( Share Sale Agreement Details 4 Agreed terms 5 1. Defined terms and interpretation 5] []
[9 Execution Share Sale Agreement Relating to China Cord Blood Corporation Purchaser Golden Meditech Holdings Limited ( Vendor Kam Yuen ( Share Sale Agreement Details 4 Agreed terms 5 1. Defined terms and interpretation 5] []
[China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2016 2Q16 Added 16,744 New Subscribers 2Q16 Revenue Up 12.7% YOY to RMB171.5 Million ($27.0 Million) 2Q16 Operating Income Amounted to RMB52.5 Million ($8.3 Million) Conference Call to be Held November 24, 2015 at 8:00 a.m. ET HONG KONG, China, November 23, 2015 ] [FORM 6-K For the month of November 2015 CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower Form 20-F x o o o Yes o x EXPLANATORY NOTE 2 Results of Operations and Financial Condition Following this cover page are the preliminary unaudited condensed consolidated financial results for the three months and six months ended September 30, 2015]
